{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06308978",
            "orgStudyIdInfo": {
                "id": "FT819-102"
            },
            "organization": {
                "fullName": "Fate Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "FT819 in Moderate to Severe Active Lupus",
            "officialTitle": "A Phase 1 Study of FT819 in Participants With Moderate to Severe Active Lupus",
            "therapeuticArea": [
                "Immunology and Rheumatology"
            ],
            "study": "in-moderate-to-severe-active-lupus"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-03-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-09-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2042-09-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-06",
            "studyFirstSubmitQcDate": "2024-03-06",
            "studyFirstPostDateStruct": {
                "date": "2024-03-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-28",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Fate Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a phase 1 study designed to assess the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in patients with moderate to severe active systemic lupus erythematosus (SLE). The study will consist of a dose-escalation stage, followed by an expansion stage to further assess the safety and activity of FT819."
        },
        "conditionsModule": {
            "conditions": [
                "Systemic Lupus Erythematosus"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 32,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "FT819",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with moderate to severe active SLE.",
                    "interventionNames": [
                        "Drug: FT819",
                        "Drug: Fludarabine",
                        "Drug: Cyclophosphamide",
                        "Drug: Bendamustine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "FT819",
                    "description": "FT819 will be administered as a single-dose intravenous (IV) infusion at planned dose levels.",
                    "armGroupLabels": [
                        "FT819"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fludarabine",
                    "description": "Fludarabine will be administered as an IV infusion at planned dose levels.",
                    "armGroupLabels": [
                        "FT819"
                    ],
                    "otherNames": [
                        "FLUDARA"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Cyclophosphamide will be administered as an IV infusion at planned dose levels.",
                    "armGroupLabels": [
                        "FT819"
                    ],
                    "otherNames": [
                        "CYTOXAN"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Bendamustine",
                    "description": "Bendamustine will be administered as an IV infusion at planned dose levels.",
                    "armGroupLabels": [
                        "FT819"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with treatment-emergent adverse events (TEAEs)",
                    "description": "The number of participants with TEAEs will be reported.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Number of participants with serious TEAEs",
                    "description": "The number of participants with serious TEAEs will be reported.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Number of participants with adverse events of special interest (AESI)",
                    "description": "The number of participants with AESIs will be reported.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Number of participants with TEAEs by severity",
                    "description": "The number of participants with TEAEs by severity will be reported. The severity of TEAEs will be determined according to appropriate rating scales for the type of event reported.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Number of participants with dose-limiting toxicities (DLTs)",
                    "description": "The number of participants with DLTs will be reported.",
                    "timeFrame": "Up to approximately 29 days"
                },
                {
                    "measure": "Recommend Phase 2 dose (RP2D) of FT819",
                    "description": "The RP2D will be determined.",
                    "timeFrame": "Up to approximately 2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Percentage of participants achieving definition of remission in SLE (DORIS) complete remission over time",
                    "description": "Percentage of participants fulfilling DORIS complete remission at each scheduled assessment and overall will be reported.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Percentage of participants achieving DORIS clinical remission over time",
                    "description": "Percentage of participants fulfilling DORIS clinical remission at each scheduled assessment and overall will be reported.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Percentage of participants achieving lupus low disease activity state (LLDAS) over time",
                    "description": "Percentage of participants fulfilling LLDAS at each scheduled assessment and overall will be reported.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Change in Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) over time",
                    "description": "Change from baseline at each scheduled assessment in SLEDAI-2K will be reported.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Change in Physician Global Assessment (PGA) over time",
                    "description": "Change from baseline at each scheduled assessment in PGA will be reported.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Change in Functional Assessment of Chronic Illness Therapy (FACIT) over time",
                    "description": "Change from baseline at each scheduled assessment in FACIT will be reported.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Change in estimated glomerular filtration rate (eGFR) over time",
                    "description": "Change from baseline at each scheduled assessment in eGFR will be reported.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Change in urine creatinine over time",
                    "description": "Change from baseline at each scheduled assessment in urine creatinine will be reported.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Change in urine protein over time",
                    "description": "Change from baseline at each scheduled assessment in urine protein will be reported.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Change in protein to creatinine ratio over time",
                    "description": "Change from baseline at each scheduled assessment in protein to creatinine ratio will be reported.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Concomitant lupus therapies prior to and following study intervention",
                    "description": "Incidence of the use of concomitant lupus therapies prior to and following the start of study intervention will be reported.",
                    "timeFrame": "Up to approximately 2 years"
                },
                {
                    "measure": "Plasma concentration of FT819",
                    "description": "The plasma concentration of FT819 will be determined.",
                    "timeFrame": "At designated time points up to approximately 29 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female adults \u226518 years and \\<40 years of age at the time of signing the informed consent form (ICF).\n* Diagnosed with SLE by the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria.\n* Positivity for antinuclear antibody, anti-ds-DNA antibody, and/or anti-Smith antibody at screening.\n* Active SLE at screening, as defined by SLEDAI \u22658 points (with a clinical SLEDAI \u22654 points, excluding alopecia, mucosal ulcers, and fever); AND one or more major organ systems with British Isles Lupus Assessment Group (BILAG) A score, excluding musculoskeletal, mucocutaneous, and/or constitutional organ systems.\n* Failure to respond to glucocorticoids and \u22652 of the following treatments for at least 3 months: cyclophosphamide (CY), mycophenolic acid or its derivatives, belimumab, methotrexate, azathioprine, anifrolumab, rituximab, obinutuzumab, cyclosporin, tacrolimus, or voclosporin.\n\nExclusion Criteria:\n\n* Active neurological symptoms of SLE at screening.\n* Potentially irreversible organ damage related to SLE, where in the opinion of the investigator, CD19 CAR T-cell therapy would be unlikely to benefit the participant.\n* Non-malignant CNS disease such as stroke, epilepsy, or neurodegenerative disease or receipt of medications for these conditions within 2 years prior to study enrollment.\n* Prior treatment with CAR T-cell therapy within the last 6 months, allograft organ transplant, or hematopoietic stem cell transplant.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Fate Trial Disclosure",
                    "role": "CONTACT",
                    "phone": "866-875-1800",
                    "email": "FateTrialDisclosure@fatetherapeutics.com"
                }
            ],
            "locations": [
                {
                    "facility": "University of Minnesota Medical School",
                    "status": "RECRUITING",
                    "city": "Minneapolis",
                    "state": "Minnesota",
                    "zip": "55455",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 44.97997,
                        "lon": -93.26384
                    }
                },
                {
                    "facility": "University of Nebraska Medical Center",
                    "status": "RECRUITING",
                    "city": "Omaha",
                    "state": "Nebraska",
                    "zip": "68198",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.25626,
                        "lon": -95.94043
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008180",
                    "term": "Lupus Erythematosus, Systemic"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003240",
                    "term": "Connective Tissue Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11177",
                    "name": "Lupus Erythematosus, Systemic",
                    "asFound": "Systemic Lupus Erythematosus",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6464",
                    "name": "Connective Tissue Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "D000069461",
                    "term": "Bendamustine Hydrochloride"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M430",
                    "name": "Bendamustine Hydrochloride",
                    "asFound": "Inserted",
                    "relevance": "HIGH"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}